Evidence map›Paper›PMID 40212381›Full record

ArticleFrontiers in microbiology2025

Exploring the repurposed role of solithromycin as an antivirulence agent against

Rihaf Alfaraj, Fai A Alkathiri, Lama A Alamri, Najd B Alnassar, Sarah H Alanazi, Razan A Algarni, Norah S Alhabdan, Reema A Abuthnain

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rihaf AlfarajDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Fai A AlkathiriDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Lama A AlamriDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Najd B AlnassarDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Sarah H AlanaziDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Razan A AlgarniDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Norah S AlhabdanDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Reema A AbuthnainDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Objectives: This study investigates the potential of Solithromycin (SOL), a next-generation macrolide with broad-spectrum activity, to be repurposed as an antivirulence agent against Methods: Using various antibacterial assays, the antibacterial and antivirulence activities of SOL were evaluated against Results: SOL demonstrated significant antibacterial efficacy against Discussion: This study highlights the potential of SOL as an antivirulence agent, emphasizing the importance of targeting regulators, such as

Indexed as

antivirulencebiofilm inhibitionMRSAsolithromycinStaphylococcus aureusΔagrA

Identifiers

PMID40212381
PMCPMC11983655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.